Biocon launches Everolimus tablets in US

The commercial launch of Everolimus follows an USFDA approval in February 2021

54
Pharma Biocon
Representational image

Last Updated on October 7, 2021 by The Health Master

Biocon today announced the launch of Everolimus tablets, a generic version of Afinitor, in the US, the company notified via a statement.

Everolimus tablets have been introduced in four strengths of 2.5mg, 5mg, 7.5mg and 10mg, with the 10 mg tablet being a ‘day-1’ generic launch. Everolimus (Afinitor) is a prescription medication that is used to treat certain types of cancers and tumours, the statement said.

The commercial launch of Everolimus follows an USFDA approval in February 2021, it added.

Speaking in this regard, Siddharth Mittal, Chief Executive Officer and Managing Director, said, “The launch of Everolimus tablets is another important addition to our generics portfolio and underscores our commitment to bringing complex, vertically-integrated and affordable generic formulations to the market expeditiously.

We will continue our focus on innovation and enhancing capacities to launch new products that make affordable healthcare accessible to millions of patients the world over.”

According to the statement, the Everolimus launch is a further assertion of Biocon’s strategy to focus on vertically-integrated, complex Finished Dosage Formulations (FDF) in niche therapeutic areas, using in-house Active Pharmaceutical Ingredient (API) capabilities.

Afinitor is a registered trademark of Novartis AG, it further said.

Natco Pharma launches higher strength Anti Cancer generic drug

Lupin launches Droxidopa capsules

Sun Pharma launches a novel formulation for Cough management

Lincoln Pharma plans to launch Cephalosporin products

Natural Antioxidant Gamma Oryzanol launched in India

Dr. Reddy’s Labs launches Rx drug Minoxidil for treatment of hair

Govt restricts export of Syringes with or without needles

DCGI gives permission to conduct Phase III trial for two-dose C-19…

NPPA allows Cos to hike retail price of Medical Devices

Pharmacovigilance programme in India: IPC redesignated it

Zydus vaccine likely to cost Rs 300 a dose

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner